Accordingly, our previous studies have demonstrated that, in BRAF- and RAS-mutant thyroid cancer cells, combined Src and MEK1/2 inhibition synergistically inhibits growth in vitro and in vivo through the induction of apoptosis; however, these effects were not achieved in PIK3CA-mutant thyroid cancer cells [11,12]. The gene discussed is BRAF; the disease is thyroid gland carcinoma.